The Quantellect read.As of Nov 19, 2026, 10 active firms cover Stoke Therapeutics Inc: 10 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $35.00 to $60.00, a moderate spread. The average target of $44.60 sits 67% above the current $26.70. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-1.19 next quarter toward $-4.09 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS10 active firms
Buy
Strong Buy00%
Buy10100%
Neutral00%
Sell00%
Strong Sell00%
Based on 10 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$44.60
+67.0% upside
Average target across 10 active firms as of Nov 19, 2026 vs $26.70 current
Highest Target$60.00
Average Target$44.60
Lowest Target$35.00
Detailed analyst forecasts for STOK
Showing 1–10 of 10 named analysts shown · 10 active firms in the rating projection
As of Nov 19, 2026, 10 of 10 active firms rate STOK a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
STOK EPS & revenue forecast
EPS · NEXT QUARTER
$-1.19
Range $-1.43 – $-1.09 · 7 analysts · +50% YoY
Next period, 7 analysts expect Stoke Therapeutics Inc to earn $-1.19 a share (range $-1.43 – $-1.09), versus $-0.79 a year earlier. Full-year consensus is $-4.01, growing to $-4.09 the year after.
REVENUE · NEXT QUARTER
$6.8M
Range $1.5M – $11.0M · 7 analysts · +9% YoY
Revenue is expected to reach $6.8M (range $1.5M – $11.0M), +9.2% year-over-year. Full-year consensus is $34.7M, rising to $47.1M next year.
Top analysts covering Stoke Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on STOK.
#1
Laura Chico
Wedbush · Rank #55
Buy
$40.00+49.8% to target
Overall win rate
46%
+ Follow
#2
Andrew Fein
HC Wainwright & Co. · Rank #73
Buy
$35.00+31.1% to target
Overall win rate
45%
+ Follow
#3
Yatin Suneja
Guggenheim · Rank #84
Buy
$60.00+124.7% to target
Overall win rate
50%
+ Follow
#4
Jessica Fye
JP Morgan · Rank #100
Buy
$40.00+49.8% to target
Overall win rate
54%
+ Follow
#5
Keay Nakae
Chardan Capital · Rank #130
Buy
$35.00+31.1% to target
Overall win rate
41%
+ Follow
STOK stock forecast FAQ
What is STOK's average 12-month price target?+
The 10 active firms with a live target average $44.60 for Stoke Therapeutics Inc over the next 12 months, ranging from a $60.00 high to a $35.00 low, as of Nov 19, 2026.
Is STOK stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 10 active firms as of Nov 19, 2026, 10 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for STOK?+
The Street-high target is $60.00 (Guggenheim), and the Street-low is $35.00 (Chardan Capital). The average of all 10 active-firm targets is $44.60.
How many active Wall Street firms cover STOK?+
10 active firms have a recognized rating on Stoke Therapeutics Inc as of Nov 19, 2026, and 10 active firms carry a live 12-month price target.
Who is the most accurate analyst covering STOK?+
Among analysts who currently cover STOK, Laura Chico of Wedbush has the strongest overall Quantellect track record (Rank #55). Their current call is Buy with a $40.00 target.
What is Stoke Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-1.19 per share (range $-1.43 – $-1.09) across 7 analysts. Full-year EPS is projected at $-4.01, rising to $-4.09 the following year.
How much revenue is Stoke Therapeutics Inc expected to report next quarter?+
Consensus revenue is $6.8M (range $1.5M – $11.0M). Full-year revenue is projected at $34.7M, growing to $47.1M next year.
Have analysts been upgrading or downgrading STOK lately?+
As of Nov 19, 2026, 10 of 10 active firms rate STOK a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their STOK calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.